title: Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic Bifidobacterium longum.
abstract: Despite great progress in molecular-targeting drugs for cancer treatment, there are problems of disease recurrence due to cancer-cell resistance to those drugs, derived from the heterogeneity of tumors. On one hand, the low-oxygen microenvironment present in malignant tumor tissues has been regarded as a source of resistance of cancer cells against conventional therapie, such as radiation and chemotherapy. To overcome these problems, we have been developing a system to selectively deliver a large amount of anticancer drugs to malignant tumors by making use of the limiting factor, hypoxia, in tumors. Our strategy is to use hypoxia as a selective target. Here, we show methods and protocols using the nonpathogenic obligate anaerobic Bifidobacterium longum as a drug-delivery system (DDS) to target anaerobic tumor tissue.
authors: Department of Advanced Medicine for Health Promotion, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University Graduate School of Medicine, 3-1-1- Asahi, 390-8621, Matsumoto, Japan. stangch@shinshu-u.ac.jp.|Anaeropharma Science, Inc., Matsumoto, Japan. stangch@shinshu-u.ac.jp.
authors: Shun'ichiro
authors: S
authors: Taniguchi
authors: Anaeropharma Science, Inc., Matsumoto, Japan.
authors: Yuko
authors: Y
authors: Shimatani
authors: Anaeropharma Science, Inc., Matsumoto, Japan.|Tokyo Medical University, Ibaraki Medical Center, Ibaraki, Japan.
authors: Minoru
authors: M
authors: Fujimori
mesh_terms: D000818:Animals; D001644:Bifidobacterium / Q000235:genetics* / Q000378:metabolism*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005818:Genetic Engineering; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D010101:Oxygen Consumption; D051381:Rats; D014185:Transplantation, Isogeneic; D023041:Xenograft Model Antitumor Assays
keywords: Anaerobic; Bifidobacterium longum; Cancer therapy; Carrier; DDS; Hypoxia; Nonpathogenic; Oxygen; Tumor targeting